Back to results
US 12,661,395 B2Granted
Canine parvovirus
AssigneeIntervet Inc.
InventorJacqueline Pearce
Life of this patent
Estimating the term…
Abstract
The invention relates to a live attenuated parvovirus for use in the protection of an animal against parvovirus infection. The invention further relates to vaccines comprising the live attenuated parvovirus as well as methods for their production.
Claims18
A method for protecting an animal against parvovirus infection, comprising administering to the animal a pharmaceutical composition comprising
- the live attenuated parvovirus comprising a capsid gene coding for an amino acid other than Isoleucine at amino acid position 219 of the VP2 capsid protein and/or an amino acid other than Glutamine at amino acid position 386 of the VP2 capsid protein,
- wherein the pharmaceutical composition is administered to the animal as a single dose and is administered during weeks 2-20 of age of the animal, and
- wherein the animal is protected against parvovirus infection even when the animal has maternal derived antibodies (MDA) against parvovirus at the time of administration.
A method to induce a protective immune response in an animal against parvovirus even when the animal has maternally derived antibody (MDA), comprising
- administering to the animal a single dose at age 2-20 weeks, a pharmaceutical composition comprising a live attenuated parvovirus comprising a capsid gene coding for an amino acid other than Isoleucine at amino acid position 219 of the VP2 capsid protein and/or an amino acid other than Glutamine at amino acid position 386 of the VP2 capsid protein.
Dependencies are inferred from the claim text.